Episode
🚨 Hims launches GLP-1 pill, Novo Nordisk threatens to sue!!! (emergency pod with Cremieux)
- Podcast
- Hims House
- Published
- Feb 5, 2026
- Duration seconds
- 1706
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/hims-launches-glp-1-pill-novo-nordisk-threatens-to-sue-emergency-pod-with-cremieux/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/hims-launches-glp-1-pill-novo-nordisk-threatens-to-sue-emergency-pod-with-cremieux.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
EMERGENCY EPISODE!!! Hims has launched a compounded oral semaglutide (GLP-1) pill, immediately triggering legal threats from Novo Nordisk. Jonathan Stern is joined by Cremieux, a bioinformatician and leading GLP-1 researcher, to break down what Hims actually released and why the drug-delivery mechanism matters. The conversation examines liposomal delivery vs. Novo’s proprietary SNAC technology, whether Hims’ product will work at all, and whether Novo will sue / how things might shake out if they do. The episode closes with a look at unit economics, next-gen GLP-1s, and what this gambit means for Hims, Novo, and the broader obesity drug market. 00:00 Sponsor: Mochi Health 02:24 Initial reaction to the news 03:56 Science deep dive: liposomal delivery vs. SNAC 06:02 Legal implications and possible lawsuit 18:38 Future of the GLP-1 market (retatrutide, Viking, orforglipron) 25:03 Final risk assessment and conclusions Not financial, legal, or medical advice